PPARα Modulation-Based Therapy in Central Nervous System Diseases

The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of dam...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Deokho Lee, Yohei Tomita, William Allen, Kazuo Tsubota, Kazuno Negishi, Toshihide Kurihara
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	central nervous system eye peroxisome proliferator-activated receptors Science Q
Acceso en línea:	https://doaj.org/article/26a5d7450ff5404ebf3224817d91f4c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26a5d7450ff5404ebf3224817d91f4c2
record_format	dspace
spelling	oai:doaj.org-article:26a5d7450ff5404ebf3224817d91f4c22021-11-25T18:10:51ZPPARα Modulation-Based Therapy in Central Nervous System Diseases10.3390/life111111682075-1729https://doaj.org/article/26a5d7450ff5404ebf3224817d91f4c22021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1168https://doaj.org/toc/2075-1729The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.Deokho LeeYohei TomitaWilliam AllenKazuo TsubotaKazuno NegishiToshihide KuriharaMDPI AGarticlecentral nervous systemeyeperoxisome proliferator-activated receptorsScienceQENLife, Vol 11, Iss 1168, p 1168 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	central nervous system eye peroxisome proliferator-activated receptors Science Q
spellingShingle	central nervous system eye peroxisome proliferator-activated receptors Science Q Deokho Lee Yohei Tomita William Allen Kazuo Tsubota Kazuno Negishi Toshihide Kurihara PPARα Modulation-Based Therapy in Central Nervous System Diseases
description	The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors and modulators of cellular metabolism. In this regard, PPARs have recently been suggested as promising therapeutic targets for suppressing the development of CNS diseases and their progressions. While the therapeutic role of PPARγ modulation in CNS diseases has been well reviewed, the role of PPARα modulation in these diseases has not been comprehensively summarized. The current review focuses on the therapeutic roles of PPARα modulation in CNS diseases, including those affecting the brain, spinal cord, and eye, with recent advances. Our review will enable more comprehensive therapeutic approaches to modulate PPARα for the prevention of and protection from various CNS diseases.
format	article
author	Deokho Lee Yohei Tomita William Allen Kazuo Tsubota Kazuno Negishi Toshihide Kurihara
author_facet	Deokho Lee Yohei Tomita William Allen Kazuo Tsubota Kazuno Negishi Toshihide Kurihara
author_sort	Deokho Lee
title	PPARα Modulation-Based Therapy in Central Nervous System Diseases
title_short	PPARα Modulation-Based Therapy in Central Nervous System Diseases
title_full	PPARα Modulation-Based Therapy in Central Nervous System Diseases
title_fullStr	PPARα Modulation-Based Therapy in Central Nervous System Diseases
title_full_unstemmed	PPARα Modulation-Based Therapy in Central Nervous System Diseases
title_sort	pparα modulation-based therapy in central nervous system diseases
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/26a5d7450ff5404ebf3224817d91f4c2
work_keys_str_mv	AT deokholee pparamodulationbasedtherapyincentralnervoussystemdiseases AT yoheitomita pparamodulationbasedtherapyincentralnervoussystemdiseases AT williamallen pparamodulationbasedtherapyincentralnervoussystemdiseases AT kazuotsubota pparamodulationbasedtherapyincentralnervoussystemdiseases AT kazunonegishi pparamodulationbasedtherapyincentralnervoussystemdiseases AT toshihidekurihara pparamodulationbasedtherapyincentralnervoussystemdiseases
_version_	1718411486661967872

PPARα Modulation-Based Therapy in Central Nervous System Diseases

Ejemplares similares